Research ArticleDrug Development

The druggable genome and support for target identification and validation in drug development

See allHide authors and affiliations

Science Translational Medicine  29 Mar 2017:
Vol. 9, Issue 383, eaag1166
DOI: 10.1126/scitranslmed.aag1166

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

An organized way to drug the genome

Many drugs that are already approved for specific diseases have known protein targets, which may be relevant for other disease types as well. In addition, a systematic way of identifying druggable genes in various diseases should help streamline the process of developing new drugs for these targets, even if no specific drugs are available for them yet. Finan et al. designed a computational approach to do this, combining data from numerous existing genome-wide association studies to identify druggable proteins, connect them with known drugs where available, and facilitate the design of new targeted therapeutics.